Synthetic biology is hailed as the "Third Biotechnology Revolution." By 2030, the synthetic biology industry will generate an annual direct economic benefit of $1.8 trillion to $3.6 trillion for the global economy.Synthetic biology is hailed as the "Third Biotechnology Revolution." By 2030, the synthetic biology industry will generate an annual direct economic benefit of $1.8 trillion to $3.6 trillion for the global economy.
PHA (Polyhydroxyalkanoates) can completely degrade in the natural environment and is seen as the ultimate solution to replace traditional plastics. Bluepha has obtained food contact certification from the National Health Commission, becoming the first and currently the only company that can sell food-grade PHA raw materials in the Chinese, American, and European markets.
PHA (Polyhydroxyalkanoates) can completely degrade in the natural environment and is seen as the ultimate solution to replace traditional plastics. Bluepha has obtained food contact certification from the National Health Commission, becoming the first and currently the only company that can sell food-grade PHA raw materials in the Chinese, American, and European markets.
PHA (Polyhydroxyalkanoates) can completely degrade in the natural environment and is seen as the ultimate solution to replace traditional plastics. Bluepha has obtained food contact certification from the National Health Commission, becoming the first and currently the only company that can sell food-grade PHA raw materials in the Chinese, American, and European markets.
PHA (Polyhydroxyalkanoates) can completely degrade in the natural environment and is seen as the ultimate solution to replace traditional plastics. Bluepha has obtained food contact certification from the National Health Commission, becoming the first and currently the only company that can sell food-grade PHA raw materials in the Chinese, American, and European markets.
Journalist Zhou Nan from Liberation Daily
Journalist Zhou Nan from Liberation Daily
Journalist Zhou Nan from Liberation Daily
Journalist Zhou Nan from Liberation Daily
Journalist Zhou Nan from Liberation Daily
Journalist Zhou Nan from Liberation Daily
A strain is updated every half year to synthesize "green plastic"
A strain is updated every half year to synthesize "green plastic"
A strain is updated every half year to synthesize "green plastic"
A strain is updated every half year to synthesize "green plastic"
A strain is updated every half year to synthesize "green plastic"
A strain is updated every half year to synthesize "green plastic"
A strain is updated every half year to synthesize "green plastic"A strain is updated every half year to synthesize "green plastic"
In the lab of Bluepha at Beikechuang Biotechnology Industrial Park in Hongkou District, a robotic arm is busily operating petri dishes, sending tens of thousands of microbial samples into testing instruments. At the same time, the computer is automatically interpreting the data, ultimately achieving the "one in ten thousand" selection of strains. This is the R&D center of Shanghai Bluepha Microbial Technology Co., Ltd., and it is also one of the most innovative laboratories in the field of synthetic biology in China.
Synthetic biology is hailed as the "third biotechnology revolution," through which microorganisms are designed and modified to produce materials needed by humans like factories. According to McKinsey's forecast, by 2030, the synthetic biology industry will generate direct economic benefits of $1.8 trillion to $3.6 trillion annually for the global economy. Shanghai has included synthetic biology in its future health industry cluster, accelerating the innovation and industrial application of synthetic biology technologies, and fully committed to building a high-end biomanufacturing industry cluster.
Geng Qiang, a partner at Shanghai Bluepha, introduced that as the first company in China to master the large-scale industrial production of PHA (polyhydroxyalkanoates), Bluepha has successfully broken the monopoly supply in this field held by chemical industry giants from the United States, Japan, and South Korea. PHA can be completely degraded in the natural environment and is seen as the ultimate solution to replace traditional plastics.
In December 2024, Bluepha obtained food contact certification from the National Health Commission, becoming the world's first and currently the only company capable of selling food-grade PHA raw materials in the Chinese, American, and European markets.
In the laboratory of Bluepha Microbial at the North Science and Technology Innovation Park in Hongkou District, a robotic arm is busily operating petri dishes, sending tens of thousands of microbial samples into testing instruments. Meanwhile, the computer automatically interprets the data, ultimately achieving the "one in ten thousand" selection of strains. This is the R&D center of Shanghai Bluepha Microbial Technology Co., Ltd., and it is also one of the most innovative laboratories in the field of synthetic biology in China.
Synthetic biology is hailed as the "Third Biotechnology Revolution." It designs and modifies microorganisms to produce substances needed by humans, much like a factory. According to McKinsey's forecast, by 2030, the synthetic biology industry will bring about $1.8 trillion to $3.6 trillion in direct economic benefits globally each year. Shanghai has included synthetic biology in its future health industry cluster, accelerating the innovation and industrial application of synthetic biological technologies, and is fully committed to building a high-end biomanufacturing industry cluster.
Geng Qiang, a partner at Shanghai Bluepha Microbial, introduced that as the first company in China to master the large-scale industrial production of PHA (Polyhydroxyalkanoates), Bluepha has successfully broken the monopoly supply in this field held by chemical industry giants from the United States, Japan, and South Korea. PHA can be completely degraded in the natural environment and is seen as the ultimate solution to replace traditional plastics.
In December 2024, Bluepha received food contact certification from the National Health Commission, becoming the world's first and currently the only company that can sell food-grade PHA raw materials in the Chinese, American, and European markets.
In the laboratory of Bluepha Microbial at the North Science and Technology Innovation Park in Hongkou District, a robotic arm is busily operating petri dishes, sending tens of thousands of microbial samples into testing instruments. Meanwhile, the computer automatically interprets the data, ultimately achieving the "one in ten thousand" selection of strains. This is the R&D center of Shanghai Bluepha Microbial Technology Co., Ltd., and it is also one of the most innovative laboratories in the field of synthetic biology in China.In the laboratory of Bluepha Microbial at the North Science and Technology Innovation Park in Hongkou District, a robotic arm is busily operating petri dishes, sending tens of thousands of microbial samples into testing instruments. Meanwhile, the computer automatically interprets the data, ultimately achieving the "one in ten thousand" selection of strains. This is the R&D center of Shanghai Bluepha Microbial Technology Co., Ltd., and it is also one of the most innovative laboratories in the field of synthetic biology in China.
Synthetic biology is hailed as the "third biotechnology revolution," through designing and modifying microorganisms to produce substances needed by humans, much like a factory. According to McKinsey's forecast, by 2030, the synthetic biology industry will generate direct economic benefits of $18 to $36 trillion annually for the global economy. Shanghai has included synthetic biology in its future health industry cluster, accelerating innovation and industrial application of synthetic biology technology, with the aim of building a high-end biological manufacturing industry cluster.Synthetic biology is hailed as the "third biotechnology revolution," through designing and modifying microorganisms to produce substances needed by humans, much like a factory. According to McKinsey's forecast, by 2030, the synthetic biology industry will generate direct economic benefits of $18 to $36 trillion annually for the global economy. Shanghai has included synthetic biology in its future health industry cluster, accelerating innovation and industrial application of synthetic biology technology, with the aim of building a high-end biological manufacturing industry cluster.
Geng Qiang, a partner at Shanghai Bluepha Microbial, introduced that as the first company in China to master large-scale industrial production of PHA (polyhydroxyalkanoates), Bluepha has successfully broken the monopoly supply in this field held by chemical industry giants from the United States, Japan, and South Korea. PHA can completely degrade in the natural environment and is considered the ultimate solution for replacing traditional plastics.Geng Qiang, a partner at Shanghai Bluepha Microbial, introduced that as the first company in China to master large-scale industrial production of PHA (polyhydroxyalkanoates), Bluepha has successfully broken the monopoly supply in this field held by chemical industry giants from the United States, Japan, and South Korea. PHA can completely degrade in the natural environment and is considered the ultimate solution for replacing traditional plastics.
In December 2024, Bluepha obtained food contact certification from the National Health Commission, becoming the world's first and currently the only company capable of selling food-grade PHA raw materials in the Chinese, American, and European markets.In December 2024, Bluepha obtained food contact certification from the National Health Commission, becoming the world's first and currently the only company capable of selling food-grade PHA raw materials in the Chinese, American, and European markets.
Unmanned R&D Platform Empowers Rapid Iteration
Unmanned R&D Platform Empowers Rapid Iteration
An unmanned R&D platform empowers rapid iteration
An unmanned R&D platform empowers rapid iteration
An unmanned R&D platform empowers rapid iteration
An unmanned R&D platform empowers rapid iteration
An unmanned R&D platform empowers rapid iterationAn unmanned R&D platform empowers rapid iteration
Each strain of cells is 1-2 micrometers long, a microorganism factory that is only one percent the size of a hair. What Bluepha does every day in its laboratory is to "construct" and "screen" these extremely tiny, most useful strains using synthetic biology technology, and then have them produce uses that "change the world." At the core of this is the large-scale production of plastic alternatives in factories—degradable biopolymers PHA, hailed as "green plastics."
The important process of screening high-quality strains takes place in a "dark lab." This self-developed "Synbio OS" technology platform by Bluepha covers the entire process of "design-build-test-learn," achieving fully unmanned intelligent operation throughout the operational stages, which is precisely where Bluepha's core competitiveness lies.
According to Rao Chitong, Chief Scientist at Shanghai Bluepha, thanks to the empowerment of this world-class R&D platform, rapid iteration of strains and processes has been achieved. Currently, it only takes half a year to iterate one generation of strains and processes, reducing the industry average cycle of 1 to 1.5 years by about 70%.
Moreover, by rewriting the genetic code of PHA strains that originally consumed palm oil, they can now consume kitchen oils and grow faster and produce more, thereby reducing costs and increasing efficiency, achieving an environmentally friendly closed loop. Founded in 2016, Bluepha's core R&D team comes from top universities and research institutes both at home and abroad, including Peking University, Tsinghua University, Chinese Academy of Sciences, and Harvard Medical School, with backgrounds in various fields such as biology, physics, automation design, and mechanical engineering. Through interdisciplinary collaboration, the company empowers full-chain development, completing original research and development of PHA and industrialization within less than 6 years, a journey that typically takes peers 15 years. By building the dark lab, technicians can program the researchers' ideas and introduce advanced technologies such as robotics and machine vision, forming an efficient processing system. They have also successfully reduced the cost of PHA production to one-third of traditional methods through AI-driven metabolic network optimization, gene editing, and high-throughput screening, and have established the world's first 10,000-ton level intelligent PHA production line.
In the smart factory located in Yancheng, Jiangsu, the entire production process from raw materials to products is automated, with unit capacity energy consumption 45% lower than traditional processes. Additionally, it can quickly switch to producing different models of PHA, meeting customized demands.
Each strain of cells is 1-2 micrometers long, a microscopic factory that is only one-hundredth the size of a human hair. What Bluepha does every day in its laboratory is to "construct" and "screen" for the most useful of these extremely tiny strains using synthetic biology technology, and then have them produce uses that can "change the world." The core application among these is the large-scale production of plastic alternatives - biodegradable biopolymers known as "green plastics" or PHA.
The crucial process of selecting high-quality strains takes place in a "dark lab." This self-developed "Synbio OS" technology platform by Bluepha covers the entire process from "design—build—test—learn," achieving fully unmanned intelligent operation throughout all operational stages. This is precisely where Bluepha's core competitiveness lies.
Dr. Chitong Rao, Chief Scientist at Bluepha, told reporters that thanks to this world-class R&D platform, the rapid iteration of strains and processes has been achieved. Currently, it only takes half a year to iterate through one generation of strains and processes, reducing the industry average cycle of 1 to 1.5 years by about 70%.
Additionally, by rewriting the genetic code of PHA-producing strains that originally consumed palm oil, they now can feed on kitchen oils and grow faster and produce more, thus reducing costs and increasing efficiency, and achieving an environmentally friendly closed loop. Founded in 2016, Bluepha’s core R&D team comes from top institutions both domestically and internationally, such as Peking University, Tsinghua University, the Chinese Academy of Sciences, and Harvard Medical School, with backgrounds in biology, physics, automation design, mechanical engineering, and other fields. Through interdisciplinary collaboration, the company has empowered its full-chain development, completing the original research and development of PHA and its industrialization in less than 6 years, accomplishing what would typically take 15 years for others in the field. By constructing dark labs, technicians can program the researchers' ideas and introduce advanced technologies like robotics and machine vision, forming an efficient processing system. They have also successfully reduced the cost of PHA production to one-third of traditional methods through AI-driven metabolic network optimization, gene editing, and high-throughput screening, and have built the world's first 10,000-ton smart PHA production line.
In the intelligent factory located in Yancheng, Jiangsu, the entire production process from raw materials to finished products is fully automated, with unit capacity energy consumption 45% lower than traditional processes. It can also quickly switch to producing different types of PHA to meet customized demands.
Each strain of cells is 1-2 micrometers long, acting as a microorganism factory that is only one-hundredth the size of a human hair. What Bluepha's laboratory does every day is to use synthetic biology technology to "construct" and "screen" out the most useful of these extremely tiny strains, then have them produce uses that can "change the world." At the core of these applications is the mass production of alternatives to plastics in factories – biodegradable biopolymers known as "green plastics," or PHA.
The crucial process of screening high-quality strains takes place in the "dark lab." This self-developed "Synbio OS" technology platform by Bluepha covers the entire process from "design-build-test-learn," achieving fully unmanned intelligent operation throughout the operational steps, which is precisely where Bluepha's core competitiveness lies.
According to Rao Chitong, Chief Scientist at Shanghai Bluepha, thanks to the empowerment of this world-class R&D platform, rapid iteration of strains and processes has been achieved. Currently, it only takes half a year to iterate a generation of strains and processes, reducing the industry average cycle of 1 to 1.5 years by about 70%.
Meanwhile, by rewriting the genetic code of PHA strains that originally fed on palm oil, they are now able to consume kitchen oils and similar substances, growing faster and producing more, thus reducing costs and increasing efficiency, achieving an environmentally friendly closed loop. Bluepha, founded in 2016, has core R&D personnel from top domestic and international institutions such as Peking University, Tsinghua University, the Chinese Academy of Sciences, and Harvard Medical School, with backgrounds in biology, physics, automation design, mechanical engineering, and other fields. Through interdisciplinary collaboration, the company empowers its entire chain development, completing the original research and development of PHA and its industrialization in less than 6 years, a journey that took peers 15 years. By building dark labs, technicians can program researchers' ideas and introduce advanced technologies like robotics and machine vision, forming an efficient processing system. They have also successfully reduced the production cost of PHA to one-third of traditional methods through AI-driven metabolic network optimization, gene editing, and high-throughput screening, and have established the world's first 10,000-ton intelligent PHA production line.
In the smart factory located in Yancheng, Jiangsu, the entire process from raw materials to products is fully automated, with unit production energy consumption 45% lower than traditional processes. It can also quickly switch to produce different types of PHA, meeting customized needs.
The Ultimate Solution for Replacing Traditional Plastics
The Ultimate Solution for Replacing Traditional Plastics
The Ultimate Solution to Replace Traditional Plastics
The Ultimate Solution to Replace Traditional Plastics
The Ultimate Solution to Replace Traditional Plastics
The Ultimate Solution to Replace Traditional Plastics
The Ultimate Solution to Replace Traditional PlasticsThe Ultimate Solution to Replace Traditional Plastics
In the exhibition hall of Bluepha, there is a particularly eye-catching fish tank. Tropical fish are swimming joyfully, and live corals are swaying freely. A few sheets of paper made from PHA were placed inside, and by the fourth week, they had almost disappeared.
PHA is regarded as the ultimate solution to replace traditional plastics. According to third-party calculations, each ton of PHA product can reduce 3.2 tons of CO2 emissions over its entire lifecycle. If it replaces 10% of global plastic consumption, it would be equivalent to reducing 150 million tons of carbon emissions annually—close to Japan's annual emissions.
Currently, Bluepha's PHA material production has reached 8,000 tons per year and has entered the stage of large-scale application. In addition to collaborating with well-known domestic and international companies for extensive use in environmental protection, the product line now covers multiple fields including agriculture, textiles, cosmetics, food, and medical.
Recently, Bluepha launched a multi-bacterial lipid product matrix for the agricultural market. As the only lipid-based biostimulant in China, Bluepha PHA has gained widespread recognition for soil improvement, saline-alkali land restoration, and crop yield enhancement. Qiang Geng introduced that in a trial conducted in Chongming, a PHA multi-bacterial lipid compound was used for growing bok choy. The results showed that under adverse conditions, it effectively improved salinized soil, increasing the yield of bok choy by 20%.
Haoqian Zhang, co-founder of Bluepha, proposed: "Through our efforts, we aim to halve the cost of traditional products and make new products ten times more effective." Facing patent barriers from giants like the United States and Germany, Bluepha has already been approved for over 100 domestic and overseas patent applications, with the number of PHA-related patents ranking second in the world.
In the corporate showroom of Bluepha, there is a rather eye-catching fish tank. Tropical fish are swimming joyfully, and live corals are swaying freely. A few sheets of paper made from PHA, placed inside, almost disappear by the fourth week.
PHA is considered the ultimate solution to replace traditional plastics. According to third-party calculations, each ton of PHA products can reduce 3.2 tons of CO2 emissions over their entire lifecycle. If it replaces 10% of global plastic consumption, it would be equivalent to reducing 1.5 billion tons of carbon emissions annually—close to Japan's annual emissions.
Currently, Bluepha's PHA material production has reached 8,000 tons per year and has entered the stage of large-scale application. In addition to collaborating with well-known domestic and international companies for extensive use in environmental protection, the product line now covers multiple fields including agriculture, textiles, beauty, food, and medical.
Not long ago, Bluepha launched a multi-bacterial lipid product matrix for the agricultural market. As the only lipid-based biostimulant in China, Bluepha's PHA has been widely recognized for its role in soil improvement, saline-alkali land restoration, and crop yield enhancement. According to Qiang Geng, in a trial conducted in Chongming, a demonstration of growing small bok choy using a compound product of PHA multi-bacterial lipids was carried out. The results showed that under adverse conditions, it could effectively improve saline-affected soil and increase the yield of small bok choy by 20%.
Haoqian Zhang, co-founder of Bluepha, proposed: "Through our efforts, we aim to halve the cost of traditional products and make new products ten times more effective." Facing the patent barriers of giants like the United States and Germany, Bluepha has already been granted over 100 domestic and overseas patent applications, with the number of PHA-related patents ranking second in the world.
In the corporate showroom of Bluepha, there is a rather eye-catching fish tank. Tropical fish are swimming joyfully, and live corals are swaying freely. A few sheets of paper made from PHA, placed inside, almost disappear by the fourth week.In the corporate showroom of Bluepha, there is a rather eye-catching fish tank. Tropical fish are swimming joyfully, and live corals are swaying freely. A few sheets of paper made from PHA, placed inside, almost disappear by the fourth week.
PHA is considered the ultimate solution to replace traditional plastics. According to third-party calculations, each ton of PHA products can reduce 3.2 tons of CO2 emissions over their entire lifecycle. If it replaces 10% of global plastic consumption, it would be equivalent to reducing 1.5 billion tons of carbon emissions annually—close to Japan's annual emissions.PHA is regarded as the ultimate solution to replace traditional plastics. According to third-party calculations, each ton of PHA products can reduce 3.2 tons of carbon dioxide emissions over its entire lifecycle. If it replaces 10% of global plastic consumption, it would be equivalent to reducing 150 million tons of carbon emissions annually—close to Japan's annual emissions.
Currently, Bluepha's PHA material production has reached 8,000 tons per year and has entered the stage of large-scale application. In addition to collaborating with well-known domestic and international companies, using it extensively in environmental protection, the product line now covers multiple fields such as agriculture, textiles, beauty, food, and medical.Currently, Bluepha's PHA material production has reached 8,000 tons per year and has entered the stage of large-scale application. In addition to collaborating with well-known domestic and international companies, using it extensively in environmental protection, the product line now covers multiple fields such as agriculture, textiles, beauty, food, and medical.
Recently, Bluepha launched a multi-bacterial lipid product matrix for the agricultural market. As the only lipophilic agricultural biostimulant in China, Bluepha's PHA has been widely recognized for soil improvement, saline-alkali land restoration, and crop yield enhancement. According to Geng Qiang, in a trial conducted in Chongming, a demonstration planting of bok choy was carried out using a compound product of PHA multi-bacterial lipids. The results showed that under adverse conditions, it could effectively improve saline soils, increasing the yield of bok choy by 20%.Recently, Bluepha launched a multi-bacterial lipid product matrix for the agricultural market. As the only lipophilic agricultural biostimulant in China, Bluepha's PHA has been widely recognized for soil improvement, saline-alkali land restoration, and crop yield enhancement. According to Geng Qiang, in a trial conducted in Chongming, a demonstration planting of bok choy was carried out using a compound product of PHA multi-bacterial lipids. The results showed that under adverse conditions, it could effectively improve saline soils, increasing the yield of bok choy by 20%.
Zhang Haoqian, co-founder of Shanghai Bluepha, proposed: "Through our efforts, we aim to halve the cost of traditional products and make new products ten times more effective." Facing patent barriers from giants like the United States and Germany, Bluepha has been granted over 100 domestic and overseas patent applications, with the number of PHA-related patents ranking second in the world.Zhang Haoqian, co-founder of Shanghai Bluepha, proposed: "Through our efforts, we aim to halve the cost of traditional products and make new products ten times more effective." Facing patent barriers from giants like the United States and Germany, Bluepha has been granted over 100 domestic and overseas patent applications, with the number of PHA-related patents ranking second in the world.
"Defining the Next Industrial Era"
"Defining the Next Industrial Era"
"Defining the Next Industrial Era"
"Defining the Next Industrial Era"
"Defining the Next Industrial Era"
"Defining the Next Industrial Era"
"Defining the Next Industrial Era""Defining the Next Industrial Era"
In the interview, what impressed the reporter most was the innovative vitality of the Bluepha team.
In this company, which has a total of more than 200 people and a research and development team of over 100, the average age is 31. The team does not emphasize "hierarchy" but instead works together towards one goal: "to benefit everyone with synthetic biology products." Behind this ambitious vision is the strong support from the government. In 2022, Bluepha decided to move into the North Science & Innovation Biotechnology Park. After land acquisition, the Hongkou District Government adjusted the land use to R&D purposes and customized approximately 11,000 square meters of office and R&D space for Bluepha.
Rao Chitong told the reporter that Bluepha still needs to face challenges: the synthetic biology industry has only developed for more than 20 years, and it is significantly driven by policies. Public acceptance of the concept also takes time. However, the opportunities are unprecedented: currently, 70% of the world's fermentation capacity is in China, and there are clear advantages in raw materials, industrial chains, and talent domestically. For this reason, Bluepha invests 50% of its annual revenue into R&D, focusing on breakthroughs in "non-grain raw material conversion" and "ultra-high density fermentation" technologies. To date, it has raised over 1.5 billion yuan in financing.
In 2024, after Bluepha officially moved into the North Science & Innovation Biotechnology Park, the North Science & Innovation Group and Bluepha jointly funded the construction of the Tian Gong Kai Wu Innovation Incubation Center, accelerating the validation and commercialization of cutting-edge innovation projects in the biotechnology field. So far, 20 distinctive enterprises have been incubated.
The Economist once predicted: "When microorganisms become the new productive force, whoever masters the language of cell programming will define the next industrial era."
The Bluepha team shares a consensus that the synthetic biology industry, which belongs to the future, is still in its early stages of development. Only by continuously running can they remain at the forefront and embrace the moment of industrial explosion.
In the interview, what impressed the journalist most was the innovative vitality of the Bluepha team.
In this company with a total of over 200 people, including more than 100 in the R&D team, the average age is 31. The team does not emphasize "hierarchy" but is united in striving towards one goal: "To benefit everyone with synthetic biology products." Behind this ambitious vision, there is strong support from the government. In 2022, Bluepha decided to move into the North Science and Technology Innovation Biotech Park. After land acquisition, the Hongkou District Government adjusted the land use to R&D and customized approximately 11,000 square meters of office and R&D space for Bluepha.
Rao Chitong told the journalist that Bluepha still faces challenges: the synthetic biology industry has only developed for about 20 years and is significantly driven by policy. It will take time for the public to accept these new concepts. However, the opportunities are unprecedented: currently, 70% of global fermentation capacity is in China, and there are clear advantages in raw materials, industrial chains, and talent domestically. For this reason, Bluepha invests 50% of its annual revenue in R&D, focusing on breakthroughs in "non-grain raw material conversion" and "ultra-high-density fermentation" technologies. So far, it has raised over 1.5 billion yuan in funding.
In 2024, after officially moving into the North Science and Technology Innovation Biotech Park, North Science and Technology Innovation Group and Bluepha jointly invested in the establishment of the Tiangong Kaiwu Innovation Incubation Center, accelerating the concept validation and industrialization of cutting-edge innovation projects in the biotechnology field. To date, it has incubated 20 distinctive companies.
The Economist once predicted: "When microorganisms become the new productive force, whoever masters the language of cell programming will define the next industrial era."
The Bluepha team shares a consensus: the synthetic biology industry, which belongs to the future, is still in its early stages of development. Only by continuously pushing forward can they remain at the forefront and embrace the moment of industrial explosion.
In the interview, what impressed the journalist most was the innovative vitality of the Bluepha team.In the interview, what impressed the journalist most was the innovative vitality of the Bluepha team.
In this company with a total of over 200 people, including more than 100 in the R&D team, the average age is 31. The team does not emphasize "hierarchy" but is united in striving towards one goal: "To benefit everyone with synthetic biology products." Behind this ambitious vision, there is strong support from the government. In 2022, Bluepha decided to move into the North Science and Technology Innovation Biotech Park. After land acquisition, the Hongkou District Government adjusted the land use to R&D and customized approximately 11,000 square meters of office and R&D space for Bluepha.In this company of over 200 people, with a research and development team of more than 100, the average age is 31. The team does not emphasize "hierarchy" but is united in striving towards one goal: "to benefit everyone with synthetic biology products." Behind this grand vision is the strong support of the government. In 2022, Bluepha decided to move into the North Science & Technology Innovation Biotech Park. After land acquisition, the Hongkou District Government adjusted the land use to R&D and customized approximately 11,000 square meters of office and R&D space for Bluepha.
Rao Chitong told reporters that Bluepha still faces challenges: the synthetic biology industry has only developed for about 20 years, significantly driven by policy, and it will take time for the public to accept the concept. However, the opportunities are unprecedented: currently, 70% of the world's fermentation capacity is in China, with clear advantages in raw materials, industrial chains, and talent domestically. To this end, Bluepha invests 50% of its annual revenue into R&D, focusing on breakthroughs in "non-grain raw material conversion" and "ultra-high density fermentation" technologies, with current financing exceeding 1.5 billion yuan.Rao Chitong told reporters that Bluepha still faces challenges: the synthetic biology industry has only developed for about 20 years, significantly driven by policy, and it will take time for the public to accept the concept. However, the opportunities are unprecedented: currently, 70% of the world's fermentation capacity is in China, with clear advantages in raw materials, industrial chains, and talent domestically. To this end, Bluepha invests 50% of its annual revenue into R&D, focusing on breakthroughs in "non-grain raw material conversion" and "ultra-high density fermentation" technologies, with current financing exceeding 1.5 billion yuan.
In 2024, after Bluepha officially moved into the North Science & Technology Innovation Biotech Park, the North Science & Technology Innovation Group and Bluepha jointly funded the establishment of the Tiangong Kaiwu Innovation Incubation Center, accelerating the concept validation and industrialization of cutting-edge biotechnology projects. Currently, 20 distinctive enterprises have been incubated.In 2024, after Bluepha officially moved into the North Science & Technology Innovation Biotech Park, the North Science & Technology Innovation Group and Bluepha jointly funded the establishment of the Tiangong Kaiwu Innovation Incubation Center, accelerating the concept validation and industrialization of cutting-edge biotechnology projects. Currently, 20 distinctive enterprises have been incubated.
The Economist once predicted: "When microorganisms become the new productive force, whoever masters the language of cell programming will define the next industrial era."The Economist once predicted: "When microorganisms become the new productive force, whoever masters the language of cell programming will define the next industrial era."
The Bluepha team shares a consensus that the synthetic biology, which belongs to the future industry, is still in its early stages of development. Only by continuously pushing forward can they remain at the forefront and embrace the moment of industrial explosion.The Bluepha team shares a consensus that the synthetic biology, which belongs to the future industry, is still in its early stages of development. Only by continuously pushing forward can they remain at the forefront and embrace the moment of industrial explosion.
【Copyright and Disclaimer】The above information is collected and organized by PlastMatch. The copyright belongs to the original author. This article is reprinted for the purpose of providing more information, and it does not imply that PlastMatch endorses the views expressed in the article or guarantees its accuracy. If there are any errors in the source attribution or if your legitimate rights have been infringed, please contact us, and we will promptly correct or remove the content. If other media, websites, or individuals use the aforementioned content, they must clearly indicate the original source and origin of the work and assume legal responsibility on their own.
